The active ingredient in Wegovy is semaglutide in its base form
Clemmensen C, Finan B, Mller TD, DiMarchi RD, Tschp MH, Hofmann SM (2019) Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
The advantages of GLP-1 agonists include substantial clinical trial data supporting their efficacy and safety, FDA approval for weight management in certain populations, proven results with many users losing 15-20% or more of body weight, and effects on appetite that make caloric restriction feel natural
It contributes to normal sulphur amino acid metabolism, your bodys way of handling sulphur compounds.* *Authorised GB/EU health claims
It notes this framing overlooks evidence that GLP-1 medications reduce cardiovascular events in people with obesity